Online inquiry

IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5960MR)

This product GTTS-WQ5960MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IGHE gene. The antibody can be applied in Allergic diseases research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NC_000014.9
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3497
UniProt ID P01854
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ5960MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14655MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ4993MR IVTScrip™ mRNA-Anti-ITGA2B&ITGB3, C4G1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA C4G1
GTTS-WQ7988MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GX-H9
GTTS-WQ977MR IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-368
GTTS-WQ11045MR IVTScrip™ mRNA-Anti-ERBB2&ERBB3, MCLA-128(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MCLA-128
GTTS-WQ13232MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PF-05082566
GTTS-WQ7882MR IVTScrip™ mRNA-Anti-APCS, GSK-2398852(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-2398852
GTTS-WQ6115MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA COR-001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW